In Phase 3 clinical trial for metastatic pancreatic ductal adenocarcinoma, a four-drug chemotherapy treatment led to a longer overall survival than a two-drug combination.
In the Phase 3 clinical trial for metastatic pancreatic ductal adenocarcinoma, a four-drug chemotherapy treatment led to a longer overall survival than a two-drug combination.